Instrumentos de avaliação multidimensional de fragilidade para uso no cuidado de idosos com doença cardiovascular / Multidimensional frailty assessment tools for use in the care of older adults with cardiovascular disease / Instrumentos de evaluación multidimensional de la fragilidad en la atención de adultos mayores con enfermedad cardiovascular

Objetivo: identificar quais os instrumentos disponíveis para avaliação multidimensional da fragilidade em idosos com doença cardiovascular, potencialmente aplicáveis durante a realização do Processo de Enfermagem. Método: revisão sistemática conduzida em oito bases de dados/portais, para identificação de estudos que apresentassem instrumentos multidimensionais de avaliação de fragilidade em idosos com doença cardiovascular e que fossem aplicáveis ao processo de enfermagem. Resultados: foram incluídos 19 instrumentos multidimensionais. O Brief Frailty Index for Coronary Artery Disease foi desenvolvido para uso no cuidado cardiovascular de idosos. O Frailty Index for Adults e o Maastricht Frailty Screening Tool for Hospitalized Patients foram desenvolvidos para uso no Processo de Enfermagem. Conclusão: apesar de apenas um instrumento ter sido desenvolvido para o idosos com doença cardiovascular e apenas dois serem aplicáveis ao processo de enfermagem, a maioria deles tem potencial de adaptação e validação para uso nesta população durante a avaliação de enfermagem.

Objective: to identify which tools are available for multidimensional frailty assessment of older adult with cardiovascular disease and which are potentially applicable during the Nursing Process. Method: a systematic review conducted in eight databases/portals to identify studies that presented multidimensional frailty assessment tools for older adult with cardiovascular disease and that were applicable to the nursing process. Results: a total of 19 multidimensional tools were included. The Brief Frailty Index for Coronary Artery Disease was developed for use in the cardiovascular care of older adult. The Frailty Index for Adults and the Maastricht Frailty Screening Tool for Hospitalized Patients were developed for use in the Nursing Process. Conclusion: although only one tool was developed for older adults with cardiovascular disease and only two are applicable to the nursing process, most of them have the potential to be adapted and validated for use in this population during nursing assessment.

Objetivo: identificar qué instrumentos están disponibles para la evaluación multidimensional de la fragilidad en personas mayores con enfermedad cardiovascular, que se puedan aplicar en el Proceso de Enfermería. Método: revisión sistemática realizada en ocho bases de datos/portales, para identificar estudios que presentaran instrumentos multidimensionales para la evaluación de la fragilidad en adultos mayores con enfermedad cardiovascular y que fueran aplicables al proceso de enfermería. Resultados: se incluyeron 19 instrumentos multidimensionales. El Brief Frailty Index for Coronary Artery Disease se desarrolló para usarlo en el cuidado cardiovascular de las personas mayores. El Frailty Index for Adults y la Maastricht Frailty Screening Tool for Hospitalized Patients se elaboraron para ser usados en el Proceso de Enfermería. Conclusión: aunque sólo se elaboró un instrumento para adultos mayores con enfermedad cardiovascular y sólo dos son aplicables al proceso de enfermería, la mayoría de ellos tienen el potencial para ser adaptados y validados para ser usados en esa población en la evaluación de enfermería.

Impacto de la diabetes en el riesgo cardiovascular en pacientes con dislipidemia / Impact of diabetes on cardiovascular risk in patients with dyslipidemia

Resumen Objetivo: Determinar el impacto de la diabetes en el riesgo cardiovascular en pacientes con dislipidemia. Método: Estudio observacional, transversal y comparativo, en el que se determinó el riesgo cardiovascular en 100 pacientes con dislipidemia, de los cuales 50 eran diabéticos, sin complicaciones crónicas. Resultados: Ambos grupos tenían características similares en cuanto a edad, presión arterial, índice de masa corporal, niveles de c-HDL y c-LDL. Sin embargo, al comparar el porcentaje de riesgo cardiovascular, observamos que el grupo de diabéticos tenía casi el doble de riesgo cardiovascular, 13.7 contra 7.9 (p = 0.014), y la edad del corazón calculada también fue mayor en los pacientes con diabetes, 80 contra 66 años (p = 0.003). Incluso, en los pacientes diabéticos la diferencia entre la edad real y la edad del corazón fue mayor, 24 años contra 15 años (p = 0.000). Conclusión: Padecer diabetes y dislipidemia duplica el riesgo cardiovascular. En la población estudiada se encontró poco control metabólico, lo que aumenta significativamente las complicaciones en edades tempranas y la carga económica al sistema de salud y a las familias de los pacientes; por tanto, es necesario replantear las estrategias de tratamiento para mejorar el control metabólico y el pronóstico del paciente a largo plazo.

Abstract Objective: To determine the impact of diabetes on cardiovascular risk in patients with dyslipidemia. Method: Observational, cross-sectional and comparative study in which cardiovascular risk was determined at 10 years in 100 patients with dyslipidemia, of these, 50 non-diabetic patients and 50 diabetic patients. Results: Both groups had similar characteristics in terms of age, blood pressure figures, average body mass index, and HDL and LDL levels. It was observed that the diabetic group has almost double the risk compared to the dyslipidemia group, 13.7 vs. 7.9 (p = 0.014), and the calculated heart age is also higher in patients with diabetes, 80 vs. 66 years (p = 0.003). Even in patients with diabetes there is a greater difference between the real age and the age of the heart, 24 years vs. 15 years of patients without diabetes (p = 0.000). Conclusion: Having diabetes and dyslipidemia doubles the cardiovascular risk of patients. Little metabolic control was found in the population studied, which significantly increases complications at an early age and the economic burden on the health system and the families of patients, so it is necessary to rethink treatment strategies to improve metabolic control and with it the prognosis for the patient in the long term.

Wakabayashi & Daimon cardiometabolic index as an indicator to assess risk in adults. A systematic review / Índice cardiometabólico de Wakabayashi y Daimon como indicador para evaluar el riesgo en adultos. Una revisión sistemática

Objective To analyze the Wakabayashi & Daimon (2015) equation, as a predictive indicator of cardiometabolic diseases and its comparison with other indices. Design A systematic review was carried out between January and March 2023, according to the PRISMA statement. Data source Scopus, Web of Science, and PubMed databases were reviewed using “cardiometabolic index” (CMI) as the search term. Study selection The following inclusion criteria were determined: studies in adults with cardiometabolic diseases using the Wakabayashi & Daimon (2015) CMI formula in different populations; studies that validate or compare the equation or that demonstrate the effects of the intervention. Data extraction Of the 11 selected articles, the characteristics of the population, type of study, indicators for the validation of the CMI, the reported statistics and the conclusions that were recorded in a comparative table were obtained. Results and conclusions Odds ratio, hazard ratio, sensitivity, and specificity were used to assess associations, risk, effectiveness, and validity of the tests, indicating favorable relationships between the factors analyzed and the results obtained. Validation and probabilistic analysis of the CMI were performed against diverse diseases such as obesity [Man >60y=AUC=0.90 (0.75–1.00) (p=0.01), Se=100, Sp=81.8, YI=0.82 and OR 4.66 and Women >60y=AUC=0.95 (0.88–1.00), p=0.001, Se=90.0, Sp=100, YI=0.90 and OR=36.27]; cardiovascular diseases [AUC=0.617, Se=0.675, Sp=0.509; HR=1.48 (1.33, 1.65), p=<0.001], among others. In conclusion CMI is a new utility index that broadly identifies the presence of risk that leads to cardiometabolic diseases in adults. (AU)

Objetivo Analizar la ecuación de Wakabayashi et al. del 2015 como indicador de predicción de enfermedades cardiometabólicas y su comparación con otros índices.Diseño Se realizó una revisión sistemática entre enero y marzo del 2023, de acuerdo con la declaración PRISMA. Fuente de datos Se revisaron las bases de datos Scopus, Web of Science y PubMed utilizando «índice cardiometabólico» (ICM) como término de búsqueda. Selección de los estudios Se determinaron los siguientes criterios de inclusión: estudios en adultos con enfermedades cardiometabólicas que utilizaron la fórmula ICM de Wakabayashi et al. en diferentes poblaciones; que validaran o compararan la ecuación o que demostraran los efectos de la intervención. Extracción de datos De los 11 artículos seleccionados, se obtuvieron las características de la población, tipo de estudio, indicadores para la validación del ICM, la estadística reportada y las conclusiones que se registraron en una tabla comparativa. Resultados y conclusiones Para evaluar las asociaciones, el riesgo, la efectividad y la validez de las pruebas se utilizaron odds ratio (OR), hazard ratio (HR), sensibilidad y especificidad, indicando relaciones favorables entre los factores analizados y los resultados obtenidos. La validación y el análisis probabilístico del ICM se realizaron frente a diversas enfermedades como obesidad (hombres >60 años=AUC=0,90 [0,75-1,00], [p=0,01], Se=100, Sp=81,8, YI=0,82 y OR 4,66; y mujeres >60 años=AUC=0,95 [0,88-1,00], p=0,001, Se=90,0, Sp=100, YI=0,90 y OR=36,27); enfermedades cardiovasculares (AUC=0,617, Se=0,675, Sp=0,509; HR=1,48 [1,33, 1,65] p≤0,001), entre otros. En conclusión, el ICM es un nuevo índice de utilidad que identifica ampliamente la presencia de riesgo para conducir a enfermedades cardiometabólicas en adultos. (AU)

Salud cardiovascular en España basada en el Life's Essential 8 y su asociación con mortalidad general y cardiovascular: la cohorte ENRICA / Cardiovascular health in Spain based on the Life's Essential 8 and its association with all-cause and cardiovascular mortality: the ENRICA cohort

Introducción y objetivos: La American Heart Association ha desarrollado el índice Life's Essential 8 (LE8) para promover la prevención de la enfermedad cardiovascular (ECV). Este estudio examinó la distribución del LE8 en la población adulta española y su asociación con la mortalidad general y por ECV.MétodosSe analizaron datos de 11.616 personas de edad≥ años (el 50,5% mujeres) del estudio ENRICA, reclutadas en 2008-2010 y seguidas hasta 2020-2022. El LE8 incluye 8 parámetros (dieta, actividad física, exposición a la nicotina, sueño, índice de masa corporal, lípidos y glucosa en sangre y presión arterial) y se puntúa de 0 a 100. La asociación entre LE8 y mortalidad se resumió mediante hazardratio obtenidas de modelos de Cox.ResultadosEl 13,2% de los participantes (del 6,1 al 16,9% según la comunidad autónoma) mostraron mala salud cardiovascular (LE8≤49). Tras una mediana de 12,9 años de seguimiento, ocurrieron 908 muertes totales y, durante una mediana de 11,8 años de seguimiento, 207 muertes por ECV. Tras ajustar por los principales factores de confusión y comparados con el cuartil más bajo (menos saludable) de LE8, los HR (IC 95%) de mortalidad general en el segundo, el tercer y el cuarto cuartil fueron, respectivamente, 0,68 (0,56-0,83), 0,63 (0,51-0,78) y 0,53 (0,39-0,72). Los resultados correspondientes a la mortalidad cardiovascular, considerando riesgos competitivos de muerte, fueron 0,62 (0,39-0,97), 0,55 (0,32-0,93) y 0,38 (0,16-0,89).ConclusionesUna proporción sustancial de los españoles mostraron mala salud cardiovascular. Una mayor puntación de LE8, desde el segundo cuartil, se asocia con menores mortalidad general y cardiovascular. (AU)

Introduction and objectives: The American Heart Association has recently developed the Life's Essential 8 (LE8) score to encourage prevention of cardiovascular disease (CVD). This study assessed the distribution of LE8 in the Spanish adult population and its association with all-cause and CVD death.MethodsWe used data from 11 616 individuals aged 18 years and older (50.5% women) from the ENRICA study, recruited between 2008 and 2010 and followed up until 2020 to 2022. The LE8 score includes 8 metrics (diet, physical activity, nicotine exposure, sleep health, body mass index, blood lipids and glucose, and blood pressure) and ranges from 0 to 100. The association of LE8 score with mortality was summarized with hazard ratios (HR), obtained from Cox regression.ResultsIn total, 13.2% of participants (range, 6.1%-16.9% across regions) had low cardiovascular health (LE8≤49). During a median follow-up of 12.9 years, 908 total deaths occurred, and, during a median follow-up of 11.8 years, 207 CVD deaths were ascertained. After adjustment for the main potential confounders and compared with being in the least healthy (lowest) quartile of LE8, the HR (95%CI) of all-cause mortality for the second, third and fourth quartiles were 0.68 (0.56-0.83), 0.63 (0.51-0.78), and 0.53 (0.39-0.72), respectively. The corresponding figures for CVD mortality, after accounting for competing mortality risks, were 0.62 (0.39-0.97), 0.55 (0.32-0.93), and 0.38 (0.16-0.89).ConclusionsA substantial proportion of the Spanish population showed low cardiovascular health. A higher LE8 score, starting from the second quartile, was associated with lower all-cause and CVD mortality. (AU)

Asociación entre los marcadores lipídicos en la infancia/ adolescencia y los eventos cardiovasculares en la adultez: una revisión sistemática / Association between lipid markers in childhood/ adolescence and cardiovascular events in adulthood: A systematic review

Introducción. La asociación entre los marcadores lipídicos en la infancia/adolescencia y la incidencia de eventos clínicos cardiovasculares en la adultez está poco explorada en la literatura. El objetivo de esta revisión sistemática fue analizar la evidencia disponible sobre este tema. Población y métodos. Esta revisión sistemática se realizó de acuerdo con las guías PRISMA. Se realizó una búsqueda bibliográfica para detectar los estudios que evaluaron la asociación entre los niveles lipídicos en la edad pediátrica y la incidencia de eventos cardiovasculares en la edad adulta. No hubo restricciones idiomáticas ni geográficas en la búsqueda. Resultados. En total, cinco estudios observacionales (todas cohortes prospectivas) que incluyeron 43 540 pacientes fueron identificados y considerados elegibles para este estudio. Cuatro estudios evaluaron el nivel de triglicéridos; todos reportaron una asociación significativa entre este marcador en la edad pediátrica y los eventos cardiovasculares en la adultez. Un estudio reportó la misma asociación con el nivel de colesterol total, mientras que otro evidenció el valor predictivo de la lipoproteína (a) para el mismo desenlace clínico. Un solo estudio evaluó el colesterol asociado a lipoproteínas de alta densidad (C-HDL), sin encontrar una relación con el punto final de interés. El análisis del colesterol asociado a lipoproteínas de baja densidad (C-LDL) arrojó resultados contradictorios, aunque la asociación fue significativa en los estudios con un tamaño muestral más grande y con un mayor número de eventos durante el seguimiento. Conclusión. Los datos de esta revisión sugieren que las alteraciones de los marcadores lipídicos en la infancia y la adolescencia se asocian con un mayor riesgo cardiovascular en la adultez temprana y media.

Introduction. The association between lipid markers in childhood/adolescence and the incidence of clinical cardiovascular events in adulthood has been little explored in the bibliography. The objective of this systematic review was to analyze available evidence on this topic. Population and methods. This systematic review was conducted in accordance with the PRISMA guidelines. A comprehensive bibliographic search was done to find studies assessing the association between lipid levels in childhood and the incidence of cardiovascular events in adulthood. There were no language or geographic restrictions. Results. A total of 5 observational studies (all prospective cohorts) including 43 540 patients were identified and considered eligible for this study. Four studies assessed triglyceride levels; all reported a significant association between this lipid marker in childhood and cardiovascular events in adulthood. A study reported the same association with total cholesterol level, while another showed the predictive value of lipoprotein (a) for the same clinical outcome. Only one study assessed high-density lipoprotein cholesterol (HDL-C), but it did not find an association with the endpoint of interest. The analysis of lowdensity lipoprotein cholesterol (LDL-C) showed contradictory results, although the association was significant in the studies with a larger sample size and a higher number of events during follow-up. Conclusion. According to this review, alterations in lipid markers in childhood and adolescence are associated with a higher cardiovascular risk in early and middle adulthood.

Impacto de la pandemia de COVID-19 en las tendencias de mortalidad por enfermedades cardiovasculares en México, 2000-2022 / Impact of the COVID-19 pandemic on cardiovascular disease mortality trends in Mexico, 2000–2022

Objetivo: Estimar el impacto de la pandemia de COVID-19 en tendencia de la mortalidad por enfermedad cardiovascular (ECV) en México. Métodos: Se realizó un estudio ecológico donde se analizaron las defunciones por ECV reportadas en México bajo la clasificación CIE-10 con los códigos I10 al I99 para el periodo 2000 al 2022. Se calcularon las tasas de mortalidad estandarizadas por edad a nivel nacional y estatal, y posteriormente se estimó la variación porcentual anual mediante el análisis de joinpoint para conocer los cambios en la tendencia de la mortalidad en el periodo estudiado. Resultados: Se presentó un incremento de 27,96 muertes por cada 100.000 habitantes del 2000 al 2022 en México. El análisis joinpoint muestra en el periodo 2019 a 2021 un cambio porcentual anual a nivel nacional de 17.398, y posteriormente se presenta una tendencia negativa entre los años 2021-2022. Los estados como Guanajuato, Tlaxcala y Querétaro mostraron los mayores incrementos en las tendencias de la mortalidad por ECV durante la pandemia por COVID-19. Conclusiones: La tendencia de la mortalidad por ECV en México se incrementó de manera importante durante la pandemia por COVID-19.(AU)

Objective: To estimate the impact of the COVID-19 pandemic on cardiovascular disease (CVD) mortality trends in Mexico. Methods: An ecological study was conducted where deaths from CVD reported in Mexico under the ICD-10 classification with codes I10 to I99 for the period 2000–2022 were analyzed. Age-standardized mortality rates were calculated at the national and state levels, then the annual percentage variation was estimated using joinpoint analysis to know the changes in the mortality trend in the period studied. Results: There was an increase of 27.96 deaths per 100,000 inhabitants from 2000 to 2022 in Mexico. The joinpoint analysis shows in the period 2019–2021 an annual percentage change at the national level of 17,398 and subsequently a negative trend is presented between the years 2021–2022. The states of Guanajuato, Tlaxcala and Querétaro showed the largest increases in CVD mortality trends during the COVID-19 pandemic. Conclusions: The trend in CVD mortality in Mexico increased significantly during the COVID-19 pandemic.(AU)

[Usefulness of e-consultation in cardiology]. / Utilidad de la teleconsulta en cardiología.

INTRODUCTION AND OBJECTIVES: The development of IT tools and interlevel relationships in the management of the most prevalent processes has led to a semi-presential assessment approach. In cardiology, this form of assessment is possible through a close collaboration with primary care. The aim of this study is to analyze the results of our e-consultation program and to establish the effectiveness of this new form of assistance. METHODS: Single-center study that included e-consultations referred from 15 September 2021 to 30 September 2022. Subsequently, we analyzed the events in which patients were discharged directly during the e-consultation with no need for an on-site visit. RESULTS: We included 3,155 e-consultations. The mean age of the patients was 57±17.6 years. Of the consultations, 75% were answered within 48h (62% within 24h). A total of 1,988 patients completed one year of follow-up in e-consultation. Out of these, 1,278 patients (64.2%) were discharged from the e-consultation with no need for an on-site visit: 685 patients (53.5%) during the first consultation, and 593 (46.5%) upon request of a complementary test. After one year of follow-up, 13 patients (0.006%) were admitted due to cardiological pathology, and 16 patients (0.008%) died, only one due to cardiovascular causes. The mean age of the deceased was 80.5 years. CONCLUSIONS: E-consultation as a single referral system from primary care to cardiology improves patient accessibility, speeds up patient assessment and is effective for patients discharged without the need for an on-site consultation.

[Impact of diabetes on cardiovascular risk in patients with dyslipidemia]. / Impacto de la diabetes en el riesgo cardiovascular en pacientes con dislipidemia.

Objective: To determine the impact of diabetes on cardiovascular risk in patients with dyslipidemia. Method: Observational, cross-sectional and comparative study in which cardiovascular risk was determined at 10 years in 100 patients with dyslipidemia, of these, 50 non-diabetic patients and 50 diabetic patients. Results: Both groups had similar characteristics in terms of age, blood pressure figures, average body mass index, and HDL and LDL levels. It was observed that the diabetic group has almost double the risk compared to the dyslipidemia group, 13.7 vs. 7.9 (p = 0.014), and the calculated heart age is also higher in patients with diabetes, 80 vs. 66 years (p = 0.003). Even in patients with diabetes there is a greater difference between the real age and the age of the heart, 24 years vs. 15 years of patients without diabetes (p = 0.000). Conclusion: Having diabetes and dyslipidemia doubles the cardiovascular risk of patients. Little metabolic control was found in the population studied, which significantly increases complications at an early age and the economic burden on the health system and the families of patients, so it is necessary to rethink treatment strategies to improve metabolic control and with it the prognosis for the patient in the long term.

Objetivo: Determinar el impacto de la diabetes en el riesgo cardiovascular en pacientes con dislipidemia. Método: Estudio observacional, transversal y comparativo, en el que se determinó el riesgo cardiovascular en 100 pacientes con dislipidemia, de los cuales 50 eran diabéticos, sin complicaciones crónicas. Resultados: Ambos grupos tenían características similares en cuanto a edad, presión arterial, índice de masa corporal, niveles de c-HDL y c-LDL. Sin embargo, al comparar el porcentaje de riesgo cardiovascular, observamos que el grupo de diabéticos tenía casi el doble de riesgo cardiovascular, 13.7 contra 7.9 (p = 0.014), y la edad del corazón calculada también fue mayor en los pacientes con diabetes, 80 contra 66 años (p = 0.003). Incluso, en los pacientes diabéticos la diferencia entre la edad real y la edad del corazón fue mayor, 24 años contra 15 años (p = 0.000). Conclusión: Padecer diabetes y dislipidemia duplica el riesgo cardiovascular. En la población estudiada se encontró poco control metabólico, lo que aumenta significativamente las complicaciones en edades tempranas y la carga económica al sistema de salud y a las familias de los pacientes; por tanto, es necesario replantear las estrategias de tratamiento para mejorar el control metabólico y el pronóstico del paciente a largo plazo.

[Impact of the COVID-19 pandemic on cardiovascular disease mortality trends in Mexico, 2000-2022]. / Impacto de la pandemia de COVID-19 en las tendencias de mortalidad por enfermedades cardiovasculares en México, 2000-2022.

OBJECTIVE: To estimate the impact of the COVID-19 pandemic on cardiovascular disease (CVD) mortality trends in Mexico. METHODS: An ecological study was conducted where deaths from CVD reported in Mexico under the ICD-10 classification with codes I10 to I99 for the period 2000-2022 were analyzed. Age-standardized mortality rates were calculated at the national and state levels, then the annual percentage variation was estimated using joinpoint analysis to know the changes in the mortality trend in the period studied. RESULTS: There was an increase of 27.96 deaths per 100,000 inhabitants from 2000 to 2022 in Mexico. The joinpoint analysis shows in the period 2019-2021 an annual percentage change at the national level of 17,398 and subsequently a negative trend is presented between the years 2021-2022. The states of Guanajuato, Tlaxcala and Querétaro showed the largest increases in CVD mortality trends during the COVID-19 pandemic. CONCLUSIONS: The trend in CVD mortality in Mexico increased significantly during the COVID-19 pandemic.

Evidencias del efecto del grano integral en las enfermedades crónicas no transmisibles

Los cereales integrales son una categoría de alimentos fundamental para la dieta humana y representan una fuente invaluable de carbohidratos, proteínas, fibras, fitoquímicos, minerales y vitaminas. Muchos estudios han demostrado que el consumo de cereales integrales está relacionado con un menor riesgo de enfermedades crónicas no transmisibles. Sin embargo, varios de sus efectos positivos para la salud parecen desaparecer cuando se refinan los cereales. La pregunta de investigación es cuál sería el efecto de los cereales integrales en la prevención de enfermedades crónicas no transmisibles. Este artículo describe los efectos positivos del consumo de cereales integrales en la prevención de estas enfermedades. Para ello, se realiza una descripción narrativa que revisa los antecedentes disponibles sobre: a) situación epidemiológica en Chile y su relación con la alimentación; b) consumo de cereales integrales en el mundo y en Chile; y c) el efecto del consumo de cereales integrales en la reducción del riesgo de enfermedad cardiovascular. obesidad, diabetes tipo 2 y cáncer. Los antecedentes generales son muy alentadores sobre el efecto positivo del consumo de cereales integrales sobre determinadas enfermedades, especialmente las de origen metabólico. Sin embargo, la incertidumbre de algunas asociaciones negativas merece mayor atención.

Whole grains are a fundamental food category for the human diet and represent an invaluable source of carbohydrates, proteins, fibers, phytochemicals, minerals and vitamins. Many studies have shown that consumption of whole grains is linked to a lower risk of chronic non-communicable diseases. However, several of its positive health effects seem to disappear when grains are refined. The research question is what would be the effect of whole grains in the prevention of Chronic Non-Communicable Diseases. This article describes the positive effects of whole grain consumption in these diseases.To this end, a narrative description is made that reviews the available background on: a) epidemiological situation in Chile and its relationship with diet; b) consumption of whole grains in the world and in Chile; and c) the effect of whole grain consumption on reducing the risk of cardiovascular disease. obesity, type 2 diabetes, and cancer. The general background is very encouraging for a positive effect of whole grain consumption on certain diseases, especially those of metabolic origin. However, the uncertainty of some negative associations deserves further attention.

Multizonal observational study conducted by clinical practitioners on Repatha® use in patients with hyperlipidemia (ZERBINI): Colombian results / Estudio Observacional Multizonal realizado por Médicos Clínicos sobre el Uso de Repatha® en Pacientes con Hiperlipidemia (ZERBINI): resultados colombianos

Background Cardiovascular disease (CVD) represents the primary cause of death and disability globally, with elevated cholesterol as one of the leading risk factors for CVD. We describe the clinical characteristics, treatment patterns, and effectiveness of evolocumab in treating hyperlipidemia. Methods Observational study conducted through a chart review of patients with hyperlipidemia receiving evolocumab as part of clinical management in Colombia. Results This study included 115 patients treated with evolocumab. A total of 101 patients (87.8%) had a history of CVD, 13 (11.3%) familial hypercholesterolemia (FH), and 23 (20%) type 2 diabetes. Thirty-nine patients reported intolerance to any statin (33.9%). The median value of LDL-C before initiation of evolocumab was 147mg/dL (IQR: 122.5–183.7mg/dL). Within the first 3 months of treatment, LDL-C value dropped to a median value of 53mg/dL (IQR: 34.0–95.5mg/dL), showing a reduction of 63.9%. The median LDL-C values remained below 45mg/dL until the end of follow-up. Among the patients with available data, up to 61% achieved an LDL-C level below 55mg/dL at the 10–12-month follow-up. A total of 72% of patients were persistent with treatment. Safety results showed a low frequency of hospitalizations (≤2%) and treatment-emergent adverse drug reactions (5.2%). No serious adverse events were reported. Conclusions Evolocumab was associated with reductions in LDL-C levels, with a relative decrease of 63.9% within the first 3 months of treatment. Low rates of interruptions due to adverse events and adequate medication persistence was reported. (AU)

Antecedentes Las enfermedades cardiovasculares (ECV) representan la principal causa de muerte y discapacidad en todo el mundo, siendo el colesterol elevado uno de los principales factores de riesgo de ECV. El presente estudio describe las características clínicas, patrones de tratamiento y la efectividad de evolocumab en el tratamiento de la hiperlipidemia. Métodos Estudio observacional de revisión de historias clínicas de pacientes con hiperlipidemia que reciben evolocumab como parte del manejo clínico en Colombia. Resultados Se incluyeron 115 pacientes tratados con evolocumab. Un total de 101 pacientes (87,8%) presentaron antecedentes de ECV, 13 (11,3%) de hipercolesterolemia familiar y 23 (20%) de diabetes tipo 2. De los pacientes estudiados, 39% declararon intolerancia a alguna estatina (33,9%). La mediana de C-LDL antes del inicio de evolocumab fue de 147mg/dL (IQR: 122,5-183,7mg/dL). En los primeros tres meses de tratamiento, el valor de C-LDL descendió a 53mg/dL (IQR: 34,0-95,5mg/dL), siendo una reducción de 63,9%. La mediana de C-LDL se mantuvo por debajo de 45mg/dL hasta el final del seguimiento. Entre los pacientes con datos disponibles, hasta 61% alcanzó un nivel de LDL-C inferior a 55mg/dL en el seguimiento de 10-12 meses. De los pacientes analizados, 72% fue persistente al tratamiento. Los resultados de seguridad mostraron una baja frecuencia de hospitalizaciones (≤2%) y de reacciones adversas relacionadas al tratamiento (5,2%). No se notificaron acontecimientos adversos graves. Conclusiones Evolocumab se asoció con reducciones en los niveles de C-LDL, con una disminución relativa de 63,9% en los primeros tres meses de tratamiento. Se reportaron bajas tasas de interrupciones por eventos adversos y adecuada persistencia a la medicación. (AU)

Wakabayashi & Daimon cardiometabolic index as an indicator to assess risk in adults. A systematic review.

OBJECTIVE: To analyze the Wakabayashi & Daimon (2015) equation, as a predictive indicator of cardiometabolic diseases and its comparison with other indices. DESIGN: A systematic review was carried out between January and March 2023, according to the PRISMA statement. DATA SOURCE: Scopus, Web of Science, and PubMed databases were reviewed using "cardiometabolic index" (CMI) as the search term. STUDY SELECTION: The following inclusion criteria were determined: studies in adults with cardiometabolic diseases using the Wakabayashi & Daimon (2015) CMI formula in different populations; studies that validate or compare the equation or that demonstrate the effects of the intervention. DATA EXTRACTION: Of the 11 selected articles, the characteristics of the population, type of study, indicators for the validation of the CMI, the reported statistics and the conclusions that were recorded in a comparative table were obtained. RESULTS AND CONCLUSIONS: Odds ratio, hazard ratio, sensitivity, and specificity were used to assess associations, risk, effectiveness, and validity of the tests, indicating favorable relationships between the factors analyzed and the results obtained. Validation and probabilistic analysis of the CMI were performed against diverse diseases such as obesity [Man >60y=AUC=0.90 (0.75-1.00) (p=0.01), Se=100, Sp=81.8, YI=0.82 and OR 4.66 and Women >60y=AUC=0.95 (0.88-1.00), p=0.001, Se=90.0, Sp=100, YI=0.90 and OR=36.27]; cardiovascular diseases [AUC=0.617, Se=0.675, Sp=0.509; HR=1.48 (1.33, 1.65), p=<0.001], among others. In conclusion CMI is a new utility index that broadly identifies the presence of risk that leads to cardiometabolic diseases in adults.

Multizonal observational study conducted by clinical practitioners on Repatha® use in patients with hyperlipidemia (ZERBINI): Colombian results.

BACKGROUND: Cardiovascular disease (CVD) represents the primary cause of death and disability globally, with elevated cholesterol as one of the leading risk factors for CVD. We describe the clinical characteristics, treatment patterns, and effectiveness of evolocumab in treating hyperlipidemia. METHODS: Observational study conducted through a chart review of patients with hyperlipidemia receiving evolocumab as part of clinical management in Colombia. RESULTS: This study included 115 patients treated with evolocumab. A total of 101 patients (87.8%) had a history of CVD, 13 (11.3%) familial hypercholesterolemia (FH), and 23 (20%) type 2 diabetes. Thirty-nine patients reported intolerance to any statin (33.9%). The median value of LDL-C before initiation of evolocumab was 147mg/dL (IQR: 122.5-183.7mg/dL). Within the first 3 months of treatment, LDL-C value dropped to a median value of 53mg/dL (IQR: 34.0-95.5mg/dL), showing a reduction of 63.9%. The median LDL-C values remained below 45mg/dL until the end of follow-up. Among the patients with available data, up to 61% achieved an LDL-C level below 55mg/dL at the 10-12-month follow-up. A total of 72% of patients were persistent with treatment. Safety results showed a low frequency of hospitalizations (≤2%) and treatment-emergent adverse drug reactions (5.2%). No serious adverse events were reported. CONCLUSIONS: Evolocumab was associated with reductions in LDL-C levels, with a relative decrease of 63.9% within the first 3 months of treatment. Low rates of interruptions due to adverse events and adequate medication persistence was reported.

New technologies for the diagnosis, treatment, and monitoring of cardiovascular diseases.

Telemedicine enables the remote provision of medical care through information and communication technologies, facilitating data transmission, patient participation, promotion of heart-healthy habits, diagnosis, early detection of acute decompensation, and monitoring and follow-up of cardiovascular diseases. Wearable devices have multiple clinical applications, ranging from arrhythmia detection to remote monitoring of chronic diseases and risk factors. Integrating these technologies safely and effectively into routine clinical practice will require a multidisciplinary approach. Technological advances and data management will increase telemonitoring strategies, which will allow greater accessibility and equity, as well as more efficient and accurate patient care. However, there are still unresolved issues, such as identifying the most appropriate technological infrastructure, integrating these data into medical records, and addressing the digital divide, which can hamper patients' adoption of remote care. This article provides an updated overview of digital tools for a more comprehensive approach to atrial fibrillation, heart failure, risk factors, and treatment adherence.

Riesgo de enfermedad cardiovascular e indicadores de adiposidad corporal y su relación con el riesgo psicosocial en trabajadores del sector económico de comercio / Indicadores de risco de doenças cardiovasculares e de adiposidade corporal e sua relação com o risco psicossocial em trabalhadores do setor econômico do comércio / Cardiovascular disease risk and body adiposity indicators and their relationship with psychosocial risk in workers of the commerce economic sector

Resumen Introducción Cada año a nivel mundial se presentan millones de muertes y lesiones no mortales por inadecuadas prácticas en salud laboral, muertes por cardiopatías isquémicas y accidente cerebrovascular son causadas por largas jornadas y altas cargas laborales. Objetivo Identificar el grado de correlación del riesgo psicosocial con el riesgo de enfermedad cardiovascular e indicadores de adiposidad corporal: IMC (índice de masa corporal), PA (perímetro abdominal) y BFP (porcentaje de grasa corporal) en trabajadores del sector económico de comercio. Método Estudio de enfoque cuantitativo y alcance correlacional no causal, con una muestra de 118 sujetos (56.7% mujeres y 43.3% hombres). Se evaluó los indicadores de adiposidad mediante el protocolo internacional para la valoración antropométrica ISAK, el riesgo cardiovascular por medio de la escala de Framingham y para evaluar el riesgo psicosocial se aplicó la Batería de Instrumentos para la Evaluación de Factores de Riesgos Psicosociales validada para la población colombiana. Estos datos fueron procesados y analizados estadísticamente mediante SPSS versión 28. Resultados Se destaca una relación significativa (p < .05) entre las variables en diferentes grados, en el caso de la correlación entre enfermedad cardiovascular y el riesgo psicosocial su coeficiente de correlación es de (r = .62), para la correlación entre el IMC y el riesgo psicosocial un coeficiente de (r = .52), en el caso del BFP y el riesgo psicosocial en mujeres fue de (r = .45) y en hombres de (r = .67) y para el PA y el riesgo psicosocial, su coeficiente de correlación fue de (r = .42) y (r = .64) respectivamente. Conclusión Existe una correlación positiva y fuerte entre el riesgo psicosocial y el riesgo de enfermedad cardiovascular, del mismo modo, entre el IMC y el riesgo psicosocial. En el caso del BFP y el riesgo psicosocial, el grado de correlación fue moderado en mujeres y fuerte en hombres al igual que en la correlación entre el PA y el riesgo psicosocial.

Resumo Introdução Todos os anos, em todo o mundo, ocorrem milhões de mortes e lesões não fatais devido a práticas inadequadas de saúde ocupacional, as mortes por doença cardíaca isquêmica e acidente vascular cerebral são causadas por longas jornadas de trabalho e altas cargas de trabalho. Objetivo Identificar o grau de correlação do risco psicossocial com o risco de doenças cardiovasculares e com os indicadores de adiposidade corporal: IMC (índice de massa corporal), PA (circunferência abdominal) e PBC (percentagem de gordura corporal) em trabalhadores do sector econômico do comércio. Método Estudo quantitativo de âmbito correlacional não causal, com uma amostra de 118 indivíduos (56.7% mulheres e 43.3% homens). Os indicadores de adiposidade foram avaliados através do protocolo internacional de avaliação antropométrica ISAK, o risco cardiovascular foi avaliado através da escala de Framingham e o risco psicossocial foi avaliado através da Bateria de Instrumentos para a Avaliação de Factores de Risco Psicossocial validada para a população colombiana. Estes dados foram processados e analisados estatisticamente utilizando o SPSS versão 28. Resultados Existe uma relação significativa (p < .05) entre as variáveis em diferentes graus, no caso da correlação entre doença cardiovascular e risco psicossocial o seu coeficiente de correlação é (r = .62), para a correlação entre IMC e risco psicossocial um coeficiente de (r = .52), para a PAF e risco psicossocial nas mulheres um coeficiente de (r = .52). 62), para a correlação entre o IMC e o risco psicossocial um coeficiente de (r = .52), no caso da PA e do risco psicossocial nas mulheres foi (r = .45) e nos homens (r = .67) e para a PA e o risco psicossocial, o seu coeficiente de correlação foi (r = .42) e (r = .64) respetivamente. Conclusão Existe uma forte correlação positiva entre o risco psicossocial e o risco de doença cardiovascular, bem como entre o IMC e o risco psicossocial. No caso da PAF e do risco psicossocial, o grau de correlação foi moderado nas mulheres e forte nos homens, tal como a correlação entre a PA e o risco psicossocial.

Abstract Introduction Every year worldwide millions of deaths and non-fatal injuries occur due to inadequate occupational health practices, deaths from ischemic heart disease and stroke are caused by long working hours and high workloads. Objective To identify the degree of correlation of psychosocial risk with the risk of cardiovascular disease and body adiposity indicators: BMI (body mass index), AC (abdominal circumference) and BFP (body fat percentage) in workers of the commerce economic sector. Method A study with a quantitative approach and non-causal correlational scope, with a sample of 118 subjects (56.7% women and 43.3% men). Adiposity indicators were evaluated by means of the international protocol for anthropometric assessment ISAK, cardiovascular risk by means of the Framingham scale and to evaluate psychosocial risk, the Battery of Instruments for the Evaluation of Psychosocial Risk Factors validated for the Colombian population was applied. These data were processed and analyzed statistically using SPSS version 28. Results A significant relationship (p < .05) between the variables is highlighted in different degrees, in the case of the correlation between cardiovascular disease and psychosocial risk its correlation coefficient is (r =. 62), for the correlation between BMI and psychosocial risk a coefficient of (r = .52), in the case of BFP and psychosocial risk in women it was (r = .45) and in men (r = .67) and for AC and psychosocial risk, its correlation coefficient was (r = .42) and (r = .64) respectively. Conclusion There was a strong positive correlation between psychosocial risk and cardiovascular disease risk, as well as between BMI and psychosocial risk. In the case of BFP and psychosocial risk, the degree of correlation was moderate in women and strong in men, as was the correlation between AC and psychosocial risk.

Between health and pleasure: perceptions of patients with cardiovascular disease following a nutritional intervention / Entre a saúde e o prazer: percepções de pacientes com doença cardiovascular acompanhados por um programa de intervenção nutricional / Entre la salud y el placer: percepciones de pacientes con enfermedad cardiovascular seguidos de un programa de intervención nutricional

The Brazilian Cardioprotective Nutritional Program (Balance)(f) consists of a nutritional counseling strategy aiming to prevent new cardiovascular events. This qualitative investigation is a case study of Balance aiming to understand the process of food choices related to the adherence of participants to the nutritional counseling. Semi-structured interviews were conducted with 10 participants and analyzed according to thematic content analysis. Patients reported incorporating nutritional advice and how they negotiate food choices to achieve a healthy diet while maintaining the consumption of pleasurable foods, some of them recommended avoiding. The continuous tensions and conflicts between healthy and pleasurable eating which permeate patients' food choices should be addressed in nutritional counseling, enabling greater and long-lasting adherence to Balance.

O Programa Alimentar Brasileiro Cardioprotetor (Dica Br) consiste em uma estratégia de aconselhamento nutricional com o objetivo de prevenção da incidência de novos eventos cardiovasculares. Esta investigação qualitativa é um estudo de caso do Dica Br e visa compreender o processo de escolhas alimentares relacionadas à adesão dos participantes às estratégias orientadas. Aplicou-se a análise de conteúdo temática para explorar as entrevistas semiestruturadas realizadas com dez participantes. Os pacientes relataram incorporar as orientações nutricionais e como negociam suas escolhas alimentares para alcançar uma alimentação saudável mantendo o consumo de alimentos prazerosos, sendo alguns recomendados a serem evitados pelo Dica Br. As contínuas tensões e conflitos entre comer por saúde e comer por prazer que permeiam as escolhas alimentares dos pacientes devem ser abordados no aconselhamento nutricional, possibilitando maior e duradoura adesão ao Dica Br.

El Programa Alimentario Brasileño Cardioprotector (Dica Br) consiste en una estrategia de prevención de nuevos eventos cardiovasculares. Esta investigación cualitativa es un estudio de caso del Dica Br con el objetivo de comprender el proceso de elección alimentaria relacionada con la adhesión a las estrategias orientadas. Se aplicó el análisis de contenido temático para explorar las entrevistas semiestructuradas realizadas con 10 participantes. Los pacientes informaron incorporar pautas nutricionales y cómo negocian sus elecciones alimentarias para lograr una dieta saludable mientras mantienen el consumo de alimentos placenteros, algunos de los cuales se recomienda evitar. Las tensiones y conflictos continuos entre comer para la salud y comer por placer que impregnan las elecciones alimentarias deben abordarse en el asesoramiento nutricional para una mayor y duradera adherencia al Dica Br.

HEARTS en las Américas: impulsar el cambio en el sistema de salud para mejorar el control de la hipertensión en la población / HEARTS in the Americas: targeting health system change to improve population hypertension control / HEARTS nas Américas: impulsionar mudanças no sistema de saúde para melhorar o controle da hipertensão arterial na população

RESUMEN Propósito de la revisión. HEARTS en las Américas es la adaptación regional de la iniciativa mundial HEARTS, de la Organización Mundial de la Salud, para la prevención y el control de las enfermedades cardiovasculares (ECV). Su objetivo general es impulsar el cambio de la práctica clínica y de la gestión en los entornos de atención primaria, por parte de los servicios de salud, a fin de mejorar el control de la hipertensión y reducir el riesgo de ECV. En esta revisión se describe la iniciativa HEARTS en las Américas. En primer lugar, se resume la situación epidemiológica regional en cuanto a la mortalidad por ECV y las tendencias en el control de la hipertensión a nivel poblacional; a continuación, se explica la razón de ser de los principales componentes de la intervención: el sistema de manejo orientado a la atención primaria y la vía clínica de HEARTS. Por último, se examinan los factores clave para acelerar la expansión de HEARTS: los medicamentos, la atención basada en el trabajo en equipo y un sistema de monitoreo y evaluación. Resultados recientes. Hasta el momento, 33 países y territorios de América Latina y el Caribe se han comprometido a integrar este programa en toda su red de atención primaria de salud para el 2025. El aumento de la cobertura y del control de la hipertensión en los entornos de atención primaria de salud (en comparación con el modelo tradicional) es prometedor y confirma que las intervenciones que se promueven como parte de HEARTS son factibles y resultan aceptables para las comunidades, los pacientes, los prestadores de servicios de salud, los responsables de la toma de decisiones y los financiadores. En esta revisión se destacan algunos casos de implementación satisfactoria. Conclusiones. Ampliar el uso de un tratamiento eficaz de la hipertensión y optimizar el control del riesgo de ECV es una forma pragmática de acelerar la reducción de la mortalidad por ECV y, al mismo tiempo, de fortalecer los sistemas de atención primaria de salud para responder con calidad y de manera eficaz y equitativa al desafío que entrañan las enfermedades no transmisibles, no solo en los países de ingresos bajos o medianos, sino en todas las comunidades a nivel mundial.

ABSTRACT Purpose of review. HEARTS in the Americas is the regional adaptation of Global Hearts, the World Health Organization initiative for cardiovascular disease (CVD) prevention and control. Its overarching goal is to drive health services to change managerial and clinical practice in primary care settings to improve hypertension control and CVD risk management. This review describes the HEARTS in the Americas initiative. First, the regional epidemiological situation of CVD mortality and population hypertension control trends are summarized; then the rationale for its main intervention components: the primary care-oriented management system and the HEARTS Clinical Pathway are described. Finally, the key factors for accelerating the expansion of HEARTS are examined: medicines, team-based care, and a system for monitoring and evaluation. Recent findings. Thus far, 33 countries in Latin America and the Caribbean have committed to integrating this program across their primary healthcare network by 2025. The increase in hypertension coverage and control in primary health care settings compared with the traditional model is promising and confirms that the interventions under the HEARTS umbrella are feasible and acceptable to communities, patients, providers, decision-makers, and funders. This review highlights some cases of successful implementation. Summary. Scaling up effective treatment for hypertension and optimization of CVD risk management is a pragmatic way to accelerate the reduction of CVD mortality while strengthening primary healthcare systems to respond effectively, with quality, and equitably, to the challenge of non-communicable diseases, not only in low-middle income countries but in all communities globally.

RESUMO Propósito da revisão. HEARTS nas Américas é uma adaptação regional da iniciativa mundial HEARTS, da Organização Mundial da Saúde, voltada para prevenção e controle das doenças cardiovasculares (DCV) na Região das Américas. Seu objetivo geral é promover mudanças na prática clínica e na gestão da atenção primária pelos serviços de saúde a fim de melhorar o controle da hipertensão arterial e reduzir o risco de DCV. Esta revisão descreve a iniciativa HEARTS nas Américas. Primeiro, é apresentado um resumo da situação epidemiológica regional relativa à mortalidade por DCV e das tendências no controle da hipertensão arterial em nível populacional. Em seguida, são explicados os motivos por trás dos principais componentes da intervenção: o sistema de manejo focado na atenção primária e o componente clínico da HEARTS. Por fim, são examinados os principais fatores para acelerar a ampliação da HEARTS: medicamentos, atenção baseada no trabalho em equipe e um sistema de monitoramento e avaliação. Resultados recentes. Até o momento, 33 países e territórios da América Latina e do Caribe se comprometeram a integrar esse programa em toda sua rede de atenção primária à saúde até 2025. Comparado com o modelo tradicional, o aumento da cobertura e do controle da hipertensão arterial nos ambientes de atenção primária à saúde é promissor e confirma que as intervenções promovidas pela HEARTS são exequíveis e aceitas por comunidades, pacientes, prestadores de serviços de saúde, tomadores de decisão e financiadores. Nesta revisão, destacamos alguns casos nos quais a implementação foi satisfatória. Conclusões. Ampliar a aplicação de um tratamento eficaz contra a hipertensão arterial e otimizar o controle do risco de DCV são medidas pragmáticas para acelerar a redução da mortalidade por DCV e, ao mesmo tempo, fortalecer os sistemas de atenção primária à saúde para responder com qualidade, eficácia e equidade ao desafio apresentado pelas doenças não transmissíveis, não apenas nos países de baixa ou média renda, mas no mundo todo.

Nuevos factores de riesgo cardiovascular en el adulto mayor

Introducción: Se han explorado los posibles predictores no tradicionales de enfermedades cardiovasculares en personas mayores. Objetivo: Identificar los factores de riesgo no tradicionales de mortalidad por enfermedades cardiovasculares en adultos mayores. Métodos: Se realizó un estudio analítico de tipo casos y controles en pacientes adultos mayores pertenecientes a 3 áreas de salud del municipio Santiago de Cuba, durante el año 2021. Los casos fueron pacientes fallecidos por enfermedad cardiovascular de tipo ateroesclerótica y los controles, pacientes adultos mayores vivos, sin la enfermedad. Se determinó la razón de productos cruzados (OR), el intervalo de confianza (IC) y la prueba ji cuadrado para identificar los factores de riesgo que se asociaron a la mortalidad. Resultados: La fragilidad (OR= 3,380; IC: 2,476-4,615; p= 0,000) y el deterioro cognitivo (OR= 2,731; IC: 2,006-3,717; p= 0,000] mostraron asociación estadística muy significativa con la mortalidad; los pacientes con 3 o más factores de riesgo presentaron un mayor riesgo de mortalidad (OR= 4,683). Conclusiones: La fragilidad y la multimorbilidad son nuevos predictores de mortalidad por enfermedades cardiovasculares en adultos mayores, que cuando se asocian, implican mayor riesgo.

Introduction: Possible non-traditional predictors of cardiovascular diseases in older people have been explored. Objective: Identify non-traditional risk factors predictive of mortality from cardiovascular diseases in older adults. Method: An analytical case-control study was carried out on older adult patients belonging to 3 health areas of the Santiago de Cuba municipality, during the year 2021. Cases: patients who died due to atherosclerotic cardiovascular disease, and controls, older adult patients alive, without the disease. The cross-product ratio (OR), the confidence interval (CI) and the chi-square test were determined to identify the factors that were associated with the onset of the disease. Results: Frailty (OR= 3.380; CI: 2.476-4.615; p= 0.000) and cognitive impairment (OR= 2.731; CI: 2.006-3.717; p= 0.000) showed a very significant statistical association with mortality; patients with 3 or more risk factors presented a higher risk of mortality (OR= 4.683). Conclusions: Frailty and multimorbidity are new predictors of mortality from cardiovascular diseases in older adults, which when associated imply greater risk.

Relación de la enfermedad periodontal inflamatoria crónica con enfermedades sistémicas

Introducción: La enfermedad periodontal es una infección inmunoinflamatoria crónica de origen multifactorial. Puede avanzar a nivel sistémico por el paso de bacterias y sus productos al torrente sanguíneo, lo cual constituye un factor de riesgo para alteraciones sistémicas. La revisión bibliográfica se realizó de julio 2022 hasta febrero 2023. Se utilizaron las bases de datos PubMed, SciELO y Elsevier y el motor de búsqueda Google Académico. Objetivos: Describir la relación de la enfermedad periodontal inflamatoria crónica con enfermedades sistémicas. Desarrollo: La medicina periodontal estudia la relación que existe entre las periodontopatías y enfermedades sistémicas, como las cardiovasculares, cerebrovasculares, pulmonares, la renal crónica, la artritis reumatoide y el Alzheimer. Las bacterias provenientes de las bolsas periodontales pasan hacia la circulación sanguínea, producen infección metastásica y daño metastásico, mediante la producción de endotoxinas, lipopolisacáridos e inflamación metastásica. Conclusiones: La enfermedad periodontal crónica constituye un factor de riesgo para el desarrollo de enfermedades cardiovasculares, pulmonares, renales, trastornos cerebrovasculares, artritis reumatoide y el Alzheimer debido a reacciones inflamatorias producidas por microorganismos patogénicos; se establece una relación bidireccional entre estas enfermedades y las periodontopatías.

Introduction: Periodontal disease is a chronic immunoinflammatory infection of multifactorial origin. It can advance at a systemic level due to the passage of bacteria and their products into the bloodstream, which constitutes a risk factor for systemic alterations. The bibliographic review was carried out from July 2022 to February 2023. The PubMed, SciELO and Elsevier databases and the Google Scholar search engine were used. Objectives: Describe the relationship of chronic inflammatory periodontal disease with systemic diseases. Development: Periodontal medicine studies the relationship between periodontopathies and systemic diseases, such as cardiovascular, cerebrovascular, pulmonary, chronic kidney disease, rheumatoid arthritis and Alzheimer's. Bacteria from periodontal pockets pass into the blood circulation, producing metastatic infection and metastatic damage, through the production of endotoxins, lipopolysaccharides and metastatic inflammation. Conclusions: Chronic periodontal disease constitutes a risk factor for the development of cardiovascular, pulmonary, renal diseases, cerebrovascular disorders, rheumatoid arthritis and Alzheimer's due to inflammatory reactions produced by pathogenic microorganisms; A bidirectional relationship is established between these diseases and periodontopathies. The analysis of this relationship and the mechanisms by which it occurs guarantees the development of a more integrative care practice.